Snapshot · Bristol-Myers Squibb Company (BMY)

Data as of 2026-10-18T07:14:07.943Z

Fundamentals check

Market cap

$122.1B

P/E (TTM)

13.2

Gross margin

70.2%

Net margin

18.9%

ROE

46.8%

R&D / revenue

21.8%

Dividend yield

4.2%

FCF yield

9.4%

Latest dividend: $0.63/share (ex-date 2026-10-02, quarterly)

Summary

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

How it makes money

Revenue mix, latest fiscal year

• Eliquis30%
• Opdivo20.9%
• Orencia7.7%
• Revlimid6.1%
• Yervoy6%
• Pomalyst/Imnovid5.7%

Recent Events

• 2026-10-14T00:00:00.000Zpositive

  Price move: BMY rose 4.6%

  BMY 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-10-12T11:14:00.000Zpositive

  BMY Gains on Positive Phase 3 Results for RYZ101 and Admilparant

  恰逢阶段性试验结果积极，或有助于市场对药物组合的乐观情绪，但不排除其他因素的影响。

  Source: gurufocus.com

• 2026-09-08T00:00:00.000Znegative

  Price move: BMY fell 3.2%

  BMY 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-20T00:00:00.000Znegative

  Price move: BMY fell 3.2%

  BMY 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-05T00:00:00.000Znegative

  Price move: BMY fell 3.4%

  BMY 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-30T00:00:00.000Zneutral

  BMY filed 10-Q

  可能与公司披露的季度信息相关，未必直接导致股价变动，但与营运进展相关。

  Source: SEC EDGAR

Analyst view

Avg price target $65.54 from 13 analysts (last quarter)

Recent rating changes

• 2026-10-05 · Leerink Partners Downgraded → Market Perform

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-09-09SellMassacesi Cristian(officer: EVP,Chief Med Offr,Head of Dev)6,249 shares
• 2026-08-25SellHolzer Phil M(officer: SVP and Controller)500 shares

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。